Compare Heron Therapeutics Inc (HRTX) vs Union Pacific Corporation (UNP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Heron Therapeutics Inc vs Union Pacific Corporation — how do they compare? Heron Therapeutics Inc trades at $0.41 (market cap $68.01M), while Union Pacific Corporation trades at $277.07 (market cap $165.27B). The key difference: Union Pacific Corporation is far larger — about 2430.1× Heron Therapeutics Inc's market cap, and Union Pacific Corporation pays a 2.04% dividend while Heron Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Heron Therapeutics Inc for 35 Days and Union Pacific Corporation for 105 Days on average.
| HRTX | UNP | |
|---|---|---|
Market Cap | $68.01M | $165.27B |
Volume | 1,891,941 | 1,474,117 |
Sector | Health | Industrials |
52-Week High | $1.49 | $310.62 |
52-Week Low | $0.27 | $216.37 |
Typical Hold Time | 35 Days | 105 Days |
Enterprise Value | $174.75M | $194.33B |
Dividend Yield | — | 2.04% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Heron Therapeutics (HRTX) trades at $0.39, up 0.95% with a bullish technical signal from moving averages. The company reported Q2 2026 revenue of $37.7M but missed EPS estimates with a $0.03 loss. Despite negative profitability metrics, analyst consensus remains strongly positive with 89% buy ratings. Recent news highlights ongoing comparisons with peers and earnings discussions.
The outlook remains challenged by persistent losses and negative margins, though strong analyst support suggests potential upside. Key risks include execution on sales targets and achieving profitability. The stock's low price near 52-week lows presents speculative opportunity but requires careful risk management given financial performance.
Union Pacific (UNP) trades at $274.68, down 0.7% with a bearish technical signal despite strong Q2 2026 earnings beat. The railroad operator maintains robust fundamentals with 28.85% net margin and 39.7% ROE, supported by $9.3B operating cash flow. Recent developments include battery-electric locomotive deployment and progress on the Norfolk Southern combination, while analyst consensus remains bullish with $332.10 price target.
UNP presents a compelling value opportunity with 21% upside to consensus target, though merger uncertainty and fuel cost pressures create near-term volatility. The company's irreplaceable infrastructure and dividend growth streak provide long-term stability, but investors should monitor regulatory approval of the Norfolk Southern deal and operating ratio pressures from rising diesel prices.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →About Union Pacific Corporation
Omaha, Nebraska-based Union Pacific is the largest public railroad in North America. Operating on more than 30,000 miles of track in the western two thirds of the U.S., UP generated roughly $22 billion of revenue in 2021 by hauling coal, industrial products, intermodal containers, agriculture goods, chemicals, and automotive goods. UP owns about one fourth of Mexican railroad Ferromex and derives about 10% of its revenue hauling freight to and from Mexico.
Read more on UNP →
